Last update: 20/05/2020 | Total Count: 8398 | Reported by PwMS: 7872 | Reported by health care professionals (HCP): 526
| Fast Data Entry Track Entries directly into the QMENTA platform. Learn more here. |
PwMS Registries/Cohorts COVID19 datasets from participating registries and cohorts collecting information directly from PwMS. Learn more here. |
HCP Registries/Cohorts COVID19 core datasets from participating registries and cohorts collecting information via HCP. Learn more here. |
|---|---|---|
| Total number: 1172 | Total number: 6797 | Total number: 429 |
| reported by PwMS: 1075 | reported by PwMS: 6797 | |
| reported by HCP: 97 | reported by HCP: 429 | |
| with (suspected) COVID19: 119 | with (suspected) COVID19: 154 | with (suspected) COVID19: 247 |
| with confirmed lab test: 61 | with confirmed lab test: 59 | with confirmed lab test: 189 |
| different countries: 54 | different countries: 36 | different countries: 4 |
| Type of MS | Type of MS | Type of MS |
| CIS 14 - RRMS 906 - PPMS 64 - SPMS 73 | CIS 46 - RRMS 4006 - PPMS 611 - SPMS 1318 | CIS 2 - RRMS 327 - PPMS 24 - SPMS 57 |
| not sure: 115 | not sure: 120 | not sure: 5 |
| Treatment | Treatment | Treatment |
| Never Treated: 171 | Never Treated: 140 | Never Treated: 16 |
| Alemtuzumab: 22 | Alemtuzumab: 89 | Alemtuzumab: 5 |
| Cladribine: 42 | Cladribine: 125 | Cladribine: 7 |
| Dimethyl fumarate: 184 | Dimethyl fumarate: 365 | Dimethyl fumarate: 52 |
| Fingolimod: 141 | Fingolimod: 587 | Fingolimod: 44 |
| Glatimarer: 77 | Glatimarer: 441 | Glatimarer: 18 |
| Interferon: 123 | Interferon: 418 | Interferon: 21 |
| Natalizumab: 85 | Natalizumab: 421 | Natalizumab: 40 |
| Ocrelizumab: 109 | Ocrelizumab: 681 | Ocrelizumab: 72 |
| Rituximab: 31 | Rituximab: 65 | Rituximab: 44 |
| Siponimod: 14 | Siponimod: 3 | |
| Teriflunomide: 81 | Teriflunomide: 230 | Teriflunomide: 28 |
All Rights Reserved ©QMENTA 2018-2019
